Autologous stem cell therapy - Acer Therapeutics

Drug Profile

Autologous stem cell therapy - Acer Therapeutics

Alternative Names: MDIs - Acer

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Opexa Therapeutics
  • Developer Acer Therapeutics; Opexa Therapeutics
  • Class Antineoplastics; Cardiovascular therapies; Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus
  • Discontinued Heart failure

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Implant)
  • 19 Sep 2017 Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics
  • 26 Mar 2014 Autologous stem cell therapy is still in preclinical trials for Type-1 diabetes mellitus in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top